Akttyva Therapeutics

Akttyva Therapeutics is a private, early-stage biotech founded in 2021, headquartered in San Francisco with a listed office in Watertown, Massachusetts. The company is developing an evidence-based, AI-assisted drug discovery platform called AIDE v.2, which combines computational tools with experimental validation. Its initial pipeline targets diseases driven by vascular leakage, aiming to modulate endothelial vasculature function. As a pre-revenue, pre-clinical company, Akttyva's strategy hinges on validating its integrated platform to discover and advance novel therapeutics.

AIDE v.2, an award-winning AI-assisted drug-discovery platform that integrates AI tools, physics-based modeling, unique compound libraries, and experimental validation, guided by human expertise.

Akttyva competes in the crowded AI-driven drug discovery space against well-funded players like Recursion, Exscientia, and Insilico Medicine. Its differentiation lies in emphasizing the integration of human drug-hunting expertise with AI, as opposed to a fully automated approach, and its specific initial focus on vascular biology.